Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine

European Journal of Pharmacology

Volumn 479, Issue 1-3, 2003, Pages 153-158

  Kahlig, Kristopher M ^a   Galli, Aurelio ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamine; Cocaine; Dopamine transporter; Trafficking

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMPHETAMINE; COCAINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; METHYLPHENIDATE; PROTEIN KINASE C INHIBITOR; PSYCHOSTIMULANT AGENT; RESERPINE; RO 41284; UNCLASSIFIED DRUG; WIN 34428;

CELL MEMBRANE; CELL SURFACE; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; DRUG EXPOSURE; DRUG PROTEIN BINDING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 0242408679     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.08.065     Document Type: Article

References (54)

1. Burnette W.B. Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal. Chem. 68:1996;2932-2938.
2. Carneiro A.M., Ingram S.L., Beaulieu J.M., Sweeney A., Amara S.G., Thomas S.M., Caron M.G., Torres G.E. The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter. J. Neurosci. 22:2002;7045-7054.
3. Carvelli L., Moron J.A., Kahlig K.M., Ferrer J.V., Sen N., Lechleiter J.D., Leeb-Lundberg F., Merrill G., Lafer E.M., Ballou L.M., Shippenberg T.S., Javitch J.A., Lin R.Z., Galli A. PI 3-kinase regulation of dopamine uptake. J. Neurochem. 81:2002;859-869.
4. Chen N., Justice J.B. Differential effect of structural modification of human dopamine transporter on the inward and outward transport of dopamine. Brain Res. Mol. Brain Res. 75:2000;208-215.
5. Chen N., Trowbridge C.G., Justice J.B. Jr. Voltammetric studies on mechanisms of dopamine efflux in the presence of substrates and cocaine from cells expressing human norepinephrine transporter. J. Neurochem. 71:1998;653-665.
6. Cowell R.M., Kantor L., Hewlett G.H., Frey K.A., Gnegy M.E. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur. J. Pharmacol. 389:2000;59-65.
7. Daniels G.M., Amara S.G. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 274:1999;35794-35801.
8. Daws L.C., Callaghan P.D., Moron J.A., Kahlig K.M., Shippenberg T.S., Javitch J.A., Galli A. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 290:2002;1545-1550.
9. Doolen S., Zahniser N.R. Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes. J. Pharmacol. Exp. Ther. 296:2001;931-938.
10. Do Rego J.C., Syringas M., Leblond B., Costentin J., Bonnet J.J. Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the rat. Br. J. Pharmacol. 128:1999;51-60.
11. Falkenburger B.H., Barstow K.L., Mintz I.M. Dendrodendritic inhibition through reversal of dopamine transport. Science. 293:2001;2465-2470.
12. Fischer J.F., Cho A.K. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208:1979;203-209.
13. Fleckenstein A.E., Pogun S., Carroll F.I., Kuhar M.J. Recovery of dopamine transporter binding and function after intrastriatal administration of the irreversible inhibitor RTI-76 [3 beta-(3p-chlorophenyl) tropan-2 beta-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride]. J. Pharmacol. Exp. Ther. 279:1996;200-206.
14. Fleckenstein A.E., Haughey H.M., Metzger R.R., Kokoshka J.M., Riddle E.L., Hanson J.E., Gibb J.W., Hanson G.R. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur. J. Pharmacol. 382:1999;45-49.
15. Giros B. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
16. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14:1993;43-49.
17. Gulley J.M., Doolen S., Zahniser N.R. Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J. Neurochem. 83:2002;400-411.
18. Harris J.E. Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. Neuropharmacology. 12:1973;669-679.
19. Hurd Y.L., Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse. 13:1993;357-369.
20. Ingram S.L., Prasad B.M., Amara S.G. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat. Neurosci. 5:2002;971-978.
21. Iversen L.L. Role of transmitter uptake mechanisms in synaptic neurotransmission. Biophys. J. 41:1971;571-591.
22. Jones S.R., Gainetdinov R.R., Wightman R.M., Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18:1998;1979-1986.
23. Kantor L., Gnegy M.E. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J. Pharmacol. Exp. Ther. 284:1998;592-598.
24. Kantor L., Hewlett G.H., Park Y.H., Richardson-Burns S.M., Mellon M.J., Gnegy M.E. Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J. Pharmacol. Exp. Ther. 297:2001;1016-1024.
25. Khoshbouei H., Wang H., Lechleiter J.D., Javitch J.A., Galli A. Amphetamine-induced DA efflux: a voltage sensitive and intracellular Na+-dependent mechanism. J. Biol. Chem. 278:2003;12070-12077.
26. Kimmel H.L., Carroll F.I., Kuhar M.J. Dopamine transporter synthesis and degradation rate in rat striatum and nucleus accumbens using RTI-76. Neuropharmacology. 39:2000;578-585.
27. Kimmel H.L., Carroll F.I., Kuhar M.J. Withdrawal from repeated cocaine alters dopamine transporter protein turnover in the rat striatum. J. Pharmacol. Exp. Ther. 304:2003;15-21.
28. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
29. Kugaya A., Fujita M., Innis R.B. Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann. Nucl. Med. 14:2000;1-9.
30. Little K.Y., Kirkman J.A., Carroll F.I., Clark T.B., Duncan G.E. Cocaine use increases [3H]WIN 35428 binding sites in human striatum. Brain Res. 628:1993;17-25.
31. Little K.Y., Zhang L., Desmond T., Frey K.A., Dalack G.W., Cassin B.J. Striatal dopaminergic abnormalities in human cocaine users. Am. J. Psychiatry. 156:1999;238-245.
32. Little K.Y., Elmer L.W., Zhong H., Scheys J.O., Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 61:2002;436-445.
33. Loder M.K., Melikian H.E. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J. Biol. Chem. 278:2003;22168-22174.
34. Mash D.C., Pablo J., Ouyang Q., Hearn W.L., Izenwasser S. Dopamine transport function is elevated in cocaine users. J. Neurochem. 81:2002;292-300.
35. Mayfield R.D., Zahniser N.R. Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent. Mol. Pharmacol. 59:2001;113-121.
36. Melikian H.E., Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19:1999;7699-7710.
37. Nelson P.J., Rudnick G. The role of chloride ion in platelet serotonin transport. J. Biol. Chem. 257:1982;6151-6155.
38. Pierce R.C., Kalivas P.W. Repeated cocaine modifies the mechanism by which amphetamine releases dopamine. J. Neurosci. 17:1997;3254-3261.
39. Pifl C., Singer E.A. Ion dependence of carrier-mediated release in dopamine or norepinephrine transporter-transfected cells questions the hypothesis of facilitated exchange diffusion. Mol. Pharmacol. 56:1999;1047-1054.
40. Pifl C., Agneter E., Drobny H., Sitte H.H., Singer E.A. Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology. 38:1999;157-165.
41. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 237:1987;1219-1223.
42. Rudnick G., Wall S.C. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. U. S. A. 89:1992;1817-1821.
43. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., Leeb-Lundberg L.M., Carvelli L., Javitch J.A., Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6850-6855.
44. Seeman P., Niznik H.B. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 4:1990;2737-2744.
45. Sitte H.H., Huck S., Reither H., Boehm S., Singer E.A., Pifl C. Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J. Neurochem. 71:1998;1289-1297.
46. Sorkina T., Doolen S., Galperin E., Zahniser N.R., Sorkin A. Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J. Biol. Chem. 278:2003;28274-28283.
47. Staley J.K., Hearn W.L., Ruttenber A.J., Wetli C.V., Mash D.C. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J. Pharmacol. Exp. Ther. 271:1994;1678-1685.
48. Sulzer D., Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron. 5:1990;797-808.
49. Sulzer D., Pothos E., Sung H.M., Maidment N.T., Hoebel B.G., Rayport S. Weak base model of amphetamine action. Ann. N.Y. Acad. Sci. 654:1992;525-528.
50. Sulzer D., Maidment N.T., Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60:1993;527-535.
51. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15:1995;4102-4108.
52. Torres G.E., Yao W.D., Mohn A.R., Quan H., Kim K.M., Levey A.I., Staudinger J., Caron M.G. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 30:2001;121-134.
53. Torres G.E., Carneiro A., Seamans K., Fiorentini C., Sweeney A., Yao W.D., Caron M.G. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J. Biol. Chem. 278:2003;2731-2739.
54. Wilson J.M., Levey A.I., Bergeron C., Kalasinsky K., Ang L., Peretti F., Adams V.I., Smialek J., Anderson W.R., Shannak K., Deck J., Niznik H.B., Kish S.J. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 40:1996;428-439.